Regular assessments of a partnership’s value in terms of supply chain, operational efficiency, data analysis, and more can optimize and extend the product life cycle.
The drug development journey is long, expensive, resource straining, and risky. Discover how to maximize the value of early-phase material and match your development path to your IND milestones.
This white paper discusses the importance of understanding how critical process parameters can impact a product’s critical quality attributes, and how a systematic approach with validated SPR assays can help in this respect.
A pharmaceutical company was looking to partner with a CMO with commercial manufacturing capabilities, large-scale assets, multinational sites, and exemplary quality systems/U.S. FDA track records.
The journey of a novel bioconjugate into the clinic is complex and uncertain. Explore the particular challenges when moving a bioconjugate candidate from early development into the clinic.
